Affinity Asset Advisors »

Moonlake Immunot shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Moonlake Immunot (MLTX) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Moonlake Immunot

Tip: Access up to 7 years of quarterly data

All positions including Moonlake Immunot held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Moonlake Immunot by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2023-09-30 $2.9M 50k 57.00

More positions owned by Affinity Asset Advisors

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Apogee Therapeutics (APGE)
Establishment Labs Holdings Ord (ESTA)
Cymabay Therapeutics
Immunovant (IMVT)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Madrigal Pharmaceuticals (MDGL)
Xenon Pharmaceuticals (XENE)
Alkermes SHS Call Option (ALKS)
Kura Oncology (KURA)
Astria Therapeutics (ATXS)
Morphic Hldg (MORF)

View all positions for Affinity Asset Advisors

Top funds holding Moonlake Immunot

BVF
Cormorant Asset Management
venBio Select Advisor
T. Rowe Price Associates
Citadel Advisors
Federated Investors
Darwin Global Management
Holocene Advisors
Westfield Capital Management Company
Alliancebernstein
Fred Alger Management
Balyasny Asset Management
Caption Management
5AM Venture Management
Wellington Management Company

View all funds holding Moonlake Immunot